Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect. (15th September 2022)
- Record Type:
- Journal Article
- Title:
- Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect. (15th September 2022)
- Main Title:
- Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect
- Authors:
- Liu, Haitao
Zhang, Panpan
Ge, Xiaoxiao
Wu, Qiong
Han, Chuchu
Zhang, Linyang
Hua, Yuxin
Zhang, Yuxuan
Liu, Jiping
Shi, Yongheng
Wang, Bin
Wang, Xiaoping
Wang, Wei
Jiang, Yi
Zhang, Huawei
Deng, Chong
Xie, Yundong
Liu, Ying
He, Shipeng - Abstract:
- Graphical abstract: Highlights: CF-ATT was designed and synthesized, which showed a significant activity of reducing TG and TC. CF-ATT displayed potent antioxidant, anti-inflammatory and hepatoprotective effects. The hepatoprotective mechanism was through the Nrf2/NF-κB signaling pathway. Abstract: Oxidative stress and inflammation were considered to be the major mechanisms in liver damage caused by clofibrate (CF). In order to obtain lipid-lowering drugs with less liver damage, the structure of clofibrate was optimized by O-desmethyl anetholtrithione and got the target compound clofibrate-O-desmethyl anetholtrithione (CF-ATT). CF-ATT significantly reduced the levels of plasma triglycerides (TG), total cholesterol (TC) in hyperlipidemia mice induced by Triton WR-1339. In addition, CF-ATT has a significantly protective effect on the liver compared with CF. The liver weight and liver coefficient were reduced. The hepatic function indexes were also decreased, such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP). Histopathological examination of the liver revealed that inflammatory cell infiltration, nuclear degeneration, cytoplasmic loosening and hepatocyte necrosis were ameliorated by administration with CF-ATT. The hepatoprotective mechanism showed that CF-ATT significantly up-regulated Nrf2 and HO-1 protein expression and down-regulated p-NF-κB P65 expression in the liver. CF-ATT has obviously antioxidant andGraphical abstract: Highlights: CF-ATT was designed and synthesized, which showed a significant activity of reducing TG and TC. CF-ATT displayed potent antioxidant, anti-inflammatory and hepatoprotective effects. The hepatoprotective mechanism was through the Nrf2/NF-κB signaling pathway. Abstract: Oxidative stress and inflammation were considered to be the major mechanisms in liver damage caused by clofibrate (CF). In order to obtain lipid-lowering drugs with less liver damage, the structure of clofibrate was optimized by O-desmethyl anetholtrithione and got the target compound clofibrate-O-desmethyl anetholtrithione (CF-ATT). CF-ATT significantly reduced the levels of plasma triglycerides (TG), total cholesterol (TC) in hyperlipidemia mice induced by Triton WR-1339. In addition, CF-ATT has a significantly protective effect on the liver compared with CF. The liver weight and liver coefficient were reduced. The hepatic function indexes were also decreased, such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP). Histopathological examination of the liver revealed that inflammatory cell infiltration, nuclear degeneration, cytoplasmic loosening and hepatocyte necrosis were ameliorated by administration with CF-ATT. The hepatoprotective mechanism showed that CF-ATT significantly up-regulated Nrf2 and HO-1 protein expression and down-regulated p-NF-κB P65 expression in the liver. CF-ATT has obviously antioxidant and anti-inflammatory activity. These findings suggested that CF-ATT has significant hypolipidemia activity and exact hepatoprotective effect possibly through the Nrf2/NF-κB-mediated signal pathway. … (more)
- Is Part Of:
- Bioorganic & medicinal chemistry letters. Volume 72(2022)
- Journal:
- Bioorganic & medicinal chemistry letters
- Issue:
- Volume 72(2022)
- Issue Display:
- Volume 72, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 72
- Issue:
- 2022
- Issue Sort Value:
- 2022-0072-2022-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-09-15
- Subjects:
- AST aspartate transaminase -- ALP alkaline phosphatase -- CA clofibric acid -- CAT catalase -- CF clofibrate -- CF-ATT clofibrate-O-desmethyl anetholtrithione -- 13C NMR 13C-nuclear magnetic resonance -- DMAP 4-dimethylaminopyridine -- DMF N, N-dimethylformamide -- EDCI 1-ethyl-3-(3-dimethylaminopropyl) carbodimide hydrochloride -- GPX glutathione peroxidase -- GSH glutathione -- GSSG oxidized glutathione -- 1H NMR 1H-nuclear magnetic resonance -- MDA malondialdehyde -- NF-κB nuclear factor-kappa B -- Nrf2 nuclear factor erythroid-2-related factor 2 -- SOD superoxide dismutase -- TC total cholesterol -- TG triglyceride -- TBIL total bilirubin
CF-ATT -- Hypolipidemia -- Hepatoprotection -- Antioxidant -- Anti-inflammation -- Nrf2/NF-κB signal pathway
Bioorganic chemistry -- Periodicals
Pharmaceutical chemistry -- Periodicals
572 - Journal URLs:
- http://www.elsevier.com/wps/find/journaldescription.cws_home/972/description#description ↗
http://www.sciencedirect.com/science/journal/0960894X ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.bmcl.2022.128844 ↗
- Languages:
- English
- ISSNs:
- 0960-894X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2089.330000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 22398.xml